IRONWOOD PHARMACEUTICALS, INC. Foreign Income Tax Expense (Benefit), Continuing Operations
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Foreign Income Tax Expense (Benefit), Continuing Operations of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-17.
Discontinued › Expense Statement › Income Tax
us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations · last filed 2022-02-18
- IRONWOOD PHARMACEUTICALS, INC. foreign income tax expense (benefit), continuing operations for fiscal 2020 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. foreign income tax expense (benefit), continuing operations for fiscal 2019 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. foreign income tax expense (benefit), continuing operations for fiscal 2018 was $0.00.
| Period end | Foreign Income Tax Expense (Benefit), Continuing Operations 12 month |
|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-02-17 |
| 2019-12-31 | $0.00 10-K · filed 2022-02-18 |
| 2018-12-31 | $0.00 10-K · filed 2021-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |